Accurately assessing the risk of preterm birth is a difficult diagnosis with significant implications. Clinical evaluation alone is limited in its ability to predict imminent delivery among patients with signs of threatened preterm labor (PTL).
Traditional biomarker tests, such as those based on the detection of fetal fibronectin (fFN), have been reported to have poor positive predictive values (PPV) for imminent delivery. The increased chance of false positives, indicated by a lower PPV, can lead to unnecessary admissions and interventions.
The PartoSure Test is a rapid, non-invasive strip test for the detection of placental alpha microglobulin-1 (PAMG-1) in patients presenting with signs and symptoms of preterm labor.